Efrem “Ef” Epstein is the founder of Elijah’s Journey, a 501c3 focused on Suicide Awareness & Prevention, and serves on the National Action Alliance for Suicide Prevention’s Faith Communities Task Force. He is also the Chief Marketing Officer of Docz, a mental health app focused on peer-to-peer support. Ef is widely sought out as a speaker, and his writings have appeared in several publications, including The New York Post, Entrepreneur, iMarketing News, and Actuary of The Future. He holds a BA in Sociology from The Johns Hopkins University.
Rabbi Nathaniel Helfgot
Rabbi Nathaniel Helfgot is spiritual leader of Congregation Netivot Shalom in Teaneck, NJ, as well as chair of the Torah SheBaal Peh Department at SAR High School in New York City. He is also on the adjunct faculty of Yeshivat Chovevei Torah Rabbinical School, the Drisha Institute for Jewish Education, and the Wexner Heritage Program. He is a member of the IRF, RCA, and the RCBC, and serves on the board of the Etzion Foundation of Yeshivat Har Etzion. He has written and edited a number of volumes in Jewish studies and has authored dozens of essays in all areas of Jewish thought and life, including an important essay describing his own struggles with clinical depression and anxiety entitled, “Dimensions of Torment: A Young Man’s Story of Surviving Depression,” published in Jewish Action, Fall 2001.
David H. Rosmarin, PhD, ABPP
David H. Rosmarin, PhD, ABPP, is an Assistant Professor in the Department of Psychiatry at Harvard Medical School, part time, and Director of the Center for Anxiety in New York City. He is a board-certified psychologist, clinical innovator, and prolific researcher, who has authored over fifty peer-reviewed publications and one hundred abstracts focused on spirituality and mental health. Clinically, Dr. Rosmarin provides Behavior Therapy for patients presenting with anxiety, affective, psychotic, personality, and somatoform disorders, while attending to relevant spiritual factors in treatment. Dr. Rosmarin’s work has received media attention from ABC, NPR, Scientific American, The Boston Globe, and The New York Times.